The estimated Net Worth of Carsten Brunn is at least 2.9 百万$ dollars as of 25 September 2023. Carsten Brunn owns over 2,932 units of Selecta Biosciences Inc stock worth over 689,111$ and over the last 6 years he sold SELB stock worth over 220,655$. In addition, he makes 1,986,500$ as President、 Chief Executive Officer、 Director at Selecta Biosciences Inc.
Carsten has made over 20 trades of the Selecta Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 2,932 units of SELB stock worth 3,108$ on 25 September 2023.
The largest trade he's ever made was exercising 43,750 units of Selecta Biosciences Inc stock on 1 December 2019 worth over 38,500$. On average, Carsten trades about 8,252 units every 42 days since 2018. As of 25 September 2023 he still owns at least 783,081 units of Selecta Biosciences Inc stock.
You can see the complete history of Carsten Brunn stock trades at the bottom of the page.
Dr. Carsten Brunn, Ph.D. is President, Chief Executive Officer, Director of the Company, effective December 1, 2018. He has served as our President, Chief Executive Officer and member of our Board of Directors since December 2018. Prior to joining Selecta Biosciences, Inc., Dr. Brunn was the President of Pharmaceuticals for the Americas Region and a member of the Global Pharmaceutical Executive Committee at Bayer AG, a pharmaceutical company, since January 2017. Previously, he served as President of Bayer Pharmaceuticals in Japan, a role he held since March 2013. He also served as the Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing innovative pharmaceutical companies in Japan. Dr. Brunn has held a number of senior leadership positions at Eli Lilly, Novartis, Basilea and Bausch and Lomb in Europe, Asia and the United States. He currently serves on the board of directors of the Biotechnology Innovation Organization (BIO). Dr. Brunn holds a Ph.D. in Chemistry from the University of Hamburg and a Master of Science in Pharmaceutical Sciences from the University of Freiburg. He also studied at the University of Washington under a research scholarship and completed his executive education at London Business School. Dr. Brunn's experience as a senior executive of life sciences companies and knowledge of the pharmaceutical and biotechnology industries contributed to our Board of Directors' conclusion that he should serve as a director of the Company.
As the President、 Chief Executive Officer、 Director of Selecta Biosciences Inc, the total compensation of Carsten Brunn at Selecta Biosciences Inc is 1,986,500$. There are no executives at Selecta Biosciences Inc getting paid more.
Carsten Brunn is 49, he's been the President、 Chief Executive Officer、 Director of Selecta Biosciences Inc since 2018. There are 12 older and 4 younger executives at Selecta Biosciences Inc. The oldest executive at Selecta Biosciences Inc is Patrick Zenner, 73, who is the Independent Director.
Carsten's mailing address filed with the SEC is C/O SELECTA BIOSCIENCES, INC., 65 GROVE STREET, WATERTOWN, MA, 02472.
Over the last 8 years, insiders at Selecta Biosciences Inc have traded over 10,638,154$ worth of Selecta Biosciences Inc stock and bought 37,612,684 units worth 162,669,477$ . The most active insiders traders include Timothy A Springer、Advisors Llc Orbi Med Capit...、Carl L Gordon. On average, Selecta Biosciences Inc executives and independent directors trade stock every 23 days with the average trade being worth of 300,312$. The most recent stock trade was executed by Carsten Brunn on 25 September 2023, trading 2,932 units of SELB stock currently worth 3,108$.
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Selecta Biosciences Inc executives and other stock owners filed with the SEC include: